Abstract: Disclosed herein are novel and inventive methods for preparing intermediates in the synthesis of C3-substituted cephalosporins. One preferred C3-substituted cephalosporin of clinical interest is Cefovecin. Accordingly, the present invention provides for methods of preparing reactive halogen intermediates for use in the synthesis of C3-substituted cephalosporins, such as Cefovecin.

Abstract: The present invention relates to novel liquid compositions and formulations containing a thioureylene compound, a polysaccharide and a liquid vehicle. The compositions and formulations of the invention are useful for dealing with diseases and conditions associated with abnormally high thyroid hormone levels in mammals, such as humans and cats.

Abstract: The present invention relates to novel liquid compositions and formulations containing a thioureylene compound, a polysaccharide and a liquid vehicle. The compositions and formulations of the invention are useful for dealing with diseases and conditions associated with abnormally high thyroid hormone levels in mammals, such as humans and cats.

Abstract: The present invention relates to novel liquid compositions and formulations containing a thioureylene compound, a polysaccharide and a liquid vehicle. The compositions and formulations of the invention are useful for dealing with diseases and conditions associated with abnormally high thyroid hormone levels in mammals, such as humans and cats.

Abstract: An aqueous pharmaceutical suspension comprising: (i) at least one non-steroidal anti-inflammatory drug; (ii) an aqueous buffer system; (iii) xanthan gum; (iv) polyvinyl pyrrolidone; and (v) glycerol wherein the suspension is free from pregelatinized starch, amino polycarboxylic acid, microcrystalline cellulose, hydroxypropylmethyl cellulose, polyoxyethylene sorbitan monooleate, silicon dioxide and taste modifying agents selected from the group consisting of bulk sweeteners, intense sweeteners, flavoring agents and mixtures thereof.

Abstract: A composition prepared for treating animals suffering from parasites which parasites are known to be susceptible to at least one of the avermectins, milbemycins or salicylanilides, comprises for example ivermectin in an amount of from 0.1 to 10%(w/v), a solvent selected from the group consisting of glycerol formal, propylene glycol, polyethylene glycol and combinations thereof, and a salicylanilide such as closantel in a required dosage amount for the animal to be treated, typically about 2.5 mg/kg live weight of the animal to be treated, a polymeric species selected from the group consisting of polyvinylpyrrolidone and polyoxypropylene/polyoxyethylene block copolymers, the said polymeric species improving the bioavailability of closantel to the extend that blood plasma levels of the said compound greater than about 20 ppm over period of treatment are achievable.

Abstract: A topical parasiticide composition comprising: (i) a phenyl pyrazole insecticide; and/or a neonicotinoid; (ii) a macrocylic lactone and/or an aminoacetonitrile derivatives; (iii) an Insect Growth Regulator; and (iv) a 2-acyl-4-oxo-1,2,3,6,7,11b-4H-pyrazino[2,1a]isoquinoline derivative.

Abstract: An anti-parasiticidal composition presented as a topical “pour-on” product for treating animals infected by parasites which are known to be susceptible to salicylanilides, especially closantel, alone or together with at least one other anti parasitic compound of the avermectin or milbemycin type and offers enhanced bioavailability of the salicylanilide by provision of a delivery system comprising at least 20% (v/v) of one or more alcohols, and optionally including a polymeric moiety selected from the group consisting of polyvinylpyrrolidone (PVP), polyoxypropylene/polyoxyethylene block copolymers (poloxamer), and polyethylene glycols (PEG), thereby improving the bioavailability of e.g. closantel (as assessed with respect to blood plasma levels of closantel).

Abstract: An oral paste comprising: (i) at least one non-steroidal anti-inflammatory drug; (ii) at least one viscosity modifying agent; and (iii) a liquid vehicle.

Abstract: A device (10) comprises a first barrel defining a first chamber for holding a first composition. The first chamber has at least one side wall and a distal end wall defining a dispensing nozzle (22). At least one flow channel (32) is formed in the at least one side wall and distal end wall, extending across the distal end wall in helical fashion. The device (10) further comprises a second barrel (14) defining a second chamber for holding a second composition. The second chamber has at least one side wall and distal end wall. An annular seal (86) is formed at the distal end of the second barrel (14). The at least one side wall defines at least one orifice (58) proximal to the seal (86). A plunger (16) is operable to drive the second barrel (14) into the first chamber to displace the first composition out through the nozzle (22) and to bring the annular seal (86) into contact with the distal end wall of the first chamber.

Abstract: A heating device (1) is described for a container (7) of a liquid pharmaceutical product having a viscosity of 50-500 cP at 4° C. and contained within a glass container. The device (1) comprises a substantially rigid, thin-walled housing (2) defining an openable chamber for receiving the container (7), a heat source (6) in the chamber comprising a hermetically sealed package containing a super-cooled metal salt fluid or liquid and an actuator (14) for activating the super-cooled metal salt to produce heat, wherein the ratio of the volume of the metal salt to the intended volume of the product is no more than 1:1.

Abstract: An injectable aqueous composition for veterinary use containing a non-steroidal anti-inflammatory compound in an amount of from about 0.25 to 30% (w/v) together with a physiologically acceptable oxygenated polymeric surfactant in an amount of from about 0.5 to 20% (w/v).

Abstract: A pet blanket providing anti-flea properties is disclosed. The blanket is formed of an upper, permeable layer and a lower, impermeable layer, which together form a closeable pocket for receiving an insert that is impregnated with one or more anti-flea agents. As a pet reclines on the upper, permeable layer, the anti-flea agent(s) diffuse from the insert, through the permeable layer and onto the supine animal.

Abstract: A pet blanket providing anti-flea properties is disclosed. The blanket is formed of an upper, permeable layer and a lower, impermeable layer, which together form a closeable pocket for receiving an insert that is impregnated with one or more anti-flea agents. As a pet reclines on the upper, permeable layer, the anti-flea agent(s) diffuse from the insert, through the permeable layer and onto the supine animal.

Abstract: A pet blanket providing anti-flea properties is disclosed. The blanket is formed of an upper, permeable layer and a lower, impermeable layer, which together form a closeable pocket for receiving an insert that is impregnated with one or more anti-flea agents. As a pet reclines on the upper, permeable layer, the anti-flea agent(s) diffuse from the insert, through the permeable layer and onto the supine animal.

Abstract: A pet blanket providing anti-flea properties is disclosed. The blanket is formed of an upper, permeable layer and a lower, impermeable layer, which together form a closeable pocket for receiving an insert that is impregnated with one or more anti-flea agents. As a pet reclines on the upper, permeable layer, the anti-flea agent(s) diffuse from the insert, through the permeable layer and onto the supine animal.

Abstract: An injectable composition is described having a higher residual effect with reduced detrimental effects such as pain at injection site, swelling, tissue irritancy or necrosis. The composition contains as active principle a tetracycline compound, either as the free base or a salt thereof with a physiologically acceptable acid, complexed with a substantially equimolar amount of a magnesium compound, and is solubilized in a water miscible solvent system comprising glycerol formal in a an amount of about 40 (v/v); with from about 1% to about 20% (v/v) polyethylene glycol and optionally containing a pH modifier in an amount sufficient to maintain a physiologically acceptable pH. In addition, the composition may further comprise a thickener, such as polyvinyl in an amount of about 10% (w/v). The balance of the composition comprises water.

Abstract: An injectable composition of higher residual effect with reduced detrimental effects such as pain at injection site, swelling, tissue irritancy or necrosis and containing as active principle a tetracycline compound, either as the free base or a salt thereof with a physiologically acceptable acid, complexed with a substantially equimolar amount of a magnesium compound, is solubilized in a water miscible solvent system comprising, either (i) a) glycerol formal in an amount of from about 10 to 50% v/v; with b) polyethylene glycol in an amount of from about 1 to 15% v/v; or (ii) from about 25 to about 75% v/v of N-methylpyrrolidone, the composition optionally containing a pH modifier in an amount sufficient to maintain a physiochemically acceptable pH, the balance being made up with water q.s.